SCHEMBL22314933

SCHEMBL22314933

Nc1nc(-c2ccc(OC(F)(F)F)cc2)ccc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.46
SCN10A Q9Y5Y9 2/20 0.46
LTA4H P09960 1/20 0.46
MAPK14 Q16539 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 1/20 0.45
XDH P47989 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
ADORA1 P30542 2/20 0.42
SCN5A Q14524 1/20 0.41
PPARD Q03181 1/20 0.41
PIM1 P11309 1/20 0.41
ACP1 P24666 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
ENPP3 O14638 1/20 0.41
ENPP1 P22413 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20472092 0.82 KMT2A (0.52) SCN10ANPC1RAB9AMAPTPPARD
SCHEMBL22314932 0.82 FAAH (0.39) SCN10AKDM4EALDH1A1GAAHPGD
SCHEMBL22315060 0.81 SCN10A (0.47) SCN10AKDM4EALDH1A1GAAHPGD
SCHEMBL22314935 0.79 PPARD (0.42) SCN10APPARDMRGPRX4
SCHEMBL22314946 0.79 DGAT1 (0.50) SCN10AKDM4EALDH1A1GAAHPGD
SCHEMBL1241715 0.78 PTGDR2 (0.47) SCN10AGAARAB9AMAPTPPARD
SCHEMBL14729755 0.78 MEN1 (0.46) SCN10AKDM4EALDH1A1GAAHPGD
SCHEMBL5105144 0.76 MRGPRX4 (0.58) SCN10AGAARAB9AMAPTMRGPRX4
SCHEMBL5784957 0.74 MRGPRX4 (0.63) LTA4HGAARAB9AMAPTMRGPRX4
SCHEMBL12953504 0.73 APP (0.59) ALDH1A1GAANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ADORA2A 2242/4885SCN10A 24/4885LTA4H 1117/4885
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ADORA2A 2242/4885SCN10A 24/4885LTA4H 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.